News & Media

Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform

Here are the latest updates on coronavirus treatments and the Moderna, Pfizer and other vaccines

VaxiPatch™, a novel vaccination system comprised of subunit antigens, adjuvants and microneedle skin delivery: An application to influenza B/Colorado/06/2017

U.S. federal agency invests in needle-free vaccine technologies

Verndari, Inc. Announces Funding from U.S. Government Agency BARDA to Accelerate Development of VaxiPatch™ Dermal Patch Vaccine Technology

BARDA establishes four new partnerships to explore innovative vaccine delivery technologies

Verndari, Inc. Announces Publication in the Journal Vaccine of Early Data Using VaxiPatch™ Vaccine System to Administer Flu Vaccine

How a painless patch could one day deliver vaccines

Search for key to beat virus

Coronavirus vaccine could come from California, with no shot needed

Company testing Covid-19 vaccine, new delivery method at UC Davis

COVID-19 Vaccine With Patch Delivery Technology Enters Preclinical Testing at UC Davis

Verndari, Inc. Begins Preclinical Testing of COVID-19 Vaccine at University of California, Davis

COVID-19 Vaccine With Patch Delivery Technology Enters Preclinical Testing at UC Davis

Potential coronavirus vaccine being tested by researchers at UC Davis